At baseline, TRD patients exhibited enhanced pro-apoptotic mRNA expression, specifically showing increased levels of Bax, p53, and cytochrome c, whereas the mRNA of the anti-apoptotic Bcl-2 was decreased compared to healthy controls. Here, BCL2 is linked to treatment resistant depression.